We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

The development of drugs for tropical diseases, such as African sleeping sickness and leishmaniasis, is rarely a priority for commercial pharmaceutical companies.

One approach to tackling this problem has been for governments and charities to subsidise drug development. Another has been for charities to create non-profit organisations that identify drug candidates and then employ commercial companies to develop the drugs.

Such 'virtual pharmas' have been the more successful of the two approaches, say Stephen M. Maurer and colleagues in the November issue of PLoS Medicine. But they want to explore a third way, suggesting that 'open source'– or open access – drug discovery, with results being made freely available, would form an online, collaborative, community-based approach to drug development for neglected diseases

They propose a 'Tropical Diseases Initiative' that would ask scientists to share knowledge freely, and for academic institutions to donate data and research tools, in return for non-monetary rewards such as "ideological satisfaction".

The researchers also believe that bypassing patents would spur competition in drug development, as candidate drugs could be developed by anyone with an interest in doing so. Ultimately, they say, advances in technology could turn what is currently a "shoestring operation that exists mainly on the web" into an inexpensive yet practical enterprise.

Link to full article by Stephen M. Maurer et al in PLoS Medicine